This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Exact Sciences

Stocks in this article: EXAS OGXI VRTX TSPT CVM MNKD CLDA

That's why I was happy to hear Conroy say that Exact Sciences does have plans to release additional Cologuard validation data this year. New data equal to or better than what was released last year should remind investors again that Exact Sciences is a strong and underappreciated early-cancer detection investment story.

Linda M. emails, "I'm interested in your thoughts on the long or short-term growth story of OncoGenex (OGXI)."

OncoGenex suffers from the same dearth of short-term catalysts as Exact Sciences. OncoGenex and partner Teva are running twin phase III studies of OGX-011 in prostate cancer, but neither company has offered specific guidance for when data will be ready for release. The best guess I've seen is late 2012.

New drugs to treat prostate cancer drugs are hot with investors right now (witness the attention being paid to Exelixis (EXEL), Medivation (MDVN) and, of course, Dendreon (DNDN).) OncoGenex seems to be missing the party. The stock, at $16, trades for about half its value in 2009 after the OGX-011 phase II data were released and presented.

OncoGenex CEO Scott Cormack, in an interview Wednesday, says his company's stock price suffers because he can't offer investors a near-term clinical catalyst to play. He also battles lingering misperceptions that Teva was a bad choice for an OGX-011 partnership, he says. Teva, of course, is best known as a generic drug powerhouse, not a big player in new oncology drug development.

"Teva was probably not the partner that most investors expected us to choose ... but they are a very smart group and good drug developers," said Cormack in an interview Wednesday. "We were the first deal signed by Teva after they announced plans to branch out into branded oncology drugs so the market didn't quite get it."

Most importantly, Teva has put significant financial resources behind OGX-011, Cormack adds, including paying for most of the costs of the two phase III prostate cancer studies and funding a third phase III study in lung cancer that is expected to start soon.

OncoGenex today sports a $110 million enterprise value with less than 10 million shares outstanding. That's not very expensive for a company with a late-stage cancer drug, even one that's already partnered.

2 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs